Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $387.16M
Last updated: Nov 17, 2026 at 11:05 AM ET
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Earnings: Report Dates and Results
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is expected to report earnings on Mar 3, 2027. In the quarter ended Sep 30, 2026, Contineum Therapeutics, Inc. Class A Common Stock reported EPS of -$0.49, below the -$0.45 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
CTNM has an expected report date of Mar 3, 2027.
Earnings History
Of the 11 quarters below that had an estimate, CTNM beat 5 and missed 6. The widest gap in the table came in the quarter ended Mar 31, 2024, when EPS landed 166.92% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported |
|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.49 | -$0.45 | -$0.51 - -$0.40 | -8.89% | Miss | N/A | 7 | 3 up, 3 down | Nov 3, 2026 |
| Jun 30, 2026 | -$0.40 | -$0.46 | -$0.51 - -$0.38 | +13.04% | Beat | N/A | 7 | 7 up, 0 down | Jul 30, 2026 |
| Mar 31, 2026 | -$0.39 | -$0.53 | -$0.61 - -$0.46 | +26.42% | Beat | N/A | 7 | 1 up, 2 down | May 5, 2026 |
| Dec 31, 2025 | -$0.49 | -$0.65 | N/A | +24.62% | Beat | N/A | 7 | 2 up, 0 down | Mar 5, 2026 |
| Sep 30, 2025 | -$0.45 | -$0.46 | -$0.70 - $0.40 | +2.17% | Beat | N/A | 7 | 4 up, 1 down | Oct 30, 2025 |
| Jun 30, 2025 | -$0.62 | -$0.41 | -$0.69 - $0.42 | -51.22% | Miss | N/A | 6 | 1 up, 4 down | Aug 5, 2025 |
| Mar 31, 2025 | -$0.62 | -$0.57 | -$0.61 - -$0.51 | -8.77% | Miss | N/A | 5 | 0 up, 0 down | May 14, 2025 |
| Dec 31, 2024 | -$0.56 | -$0.43 | -$0.50 - -$0.37 | -30.23% | Miss | N/A | 4 | N/A | Mar 6, 2025 |
| Sep 30, 2024 | -$0.40 | -$0.42 | -$0.43 - -$0.35 | +4.76% | Beat | N/A | 4 | 0 up, 0 down | Nov 6, 2024 |
| Jun 30, 2024 | -$0.39 | -$0.35 | N/A | -11.43% | Miss | N/A | N/A | N/A | Aug 13, 2024 |
| Mar 31, 2024 | -$3.55 | -$1.33 | N/A | -166.92% | Miss | N/A | N/A | N/A | May 16, 2024 |
| Dec 31, 2023 | -$1.44 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Feb 28, 2024 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$2.18, after -$4.90 the year before. It was -$1.44 for the year ended Dec 31, 2023, the oldest of the 3 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$2.18 | N/A |
| Dec 31, 2024 | -$4.90 | N/A |
| Dec 31, 2023 | -$1.44 | N/A |
Frequently Asked Questions About CTNM
When is Contineum Therapeutics, Inc. Class A Common Stock's next earnings date?
Contineum Therapeutics, Inc. Class A Common Stock's next earnings report is expected for Mar 3, 2027.
Did CTNM beat earnings estimates last quarter?
No. Contineum Therapeutics, Inc. Class A Common Stock reported EPS of -$0.49 for the quarter ended Sep 30, 2026, below the -$0.45 estimate by 8.89%.
What EPS do analysts expect from CTNM next quarter?
The consensus EPS estimate for Contineum Therapeutics, Inc. Class A Common Stock for the quarter ending Dec 31, 2026 is -$0.50 from 10 analysts, with estimates from -$0.54 to -$0.35.
How often does CTNM beat earnings estimates?
Contineum Therapeutics, Inc. Class A Common Stock beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -4.11%.
CTNM pages: Overview, Earnings, Forecast, Financials, Competitors